Your browser doesn't support javascript.
loading
Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.
Craft, William H; Tegge, Allison N; Keith, Diana R; Shin, Hwasoo; Williams, Jacob; Athamneh, Liqa N; Stein, Jeffrey S; Chilcoat, Howard D; Le Moigne, Anne; DeVeaugh-Geiss, Angela; Bickel, Warren K.
Afiliación
  • Craft WH; Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, 1 Riverside Circle, Roanoke, VA 24016, United States; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.
  • Tegge AN; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States; Department of Statistics, Virginia Tech, Blacksburg, VA 24061, United States.
  • Keith DR; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.
  • Shin H; Department of Statistics, Virginia Tech, Blacksburg, VA 24061, United States.
  • Williams J; Department of Statistics, Virginia Tech, Blacksburg, VA 24061, United States.
  • Athamneh LN; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.
  • Stein JS; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.
  • Chilcoat HD; Indivior, Inc, North Chesterfield, VA 23235, United States; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.
  • Le Moigne A; Indivior, Inc, North Chesterfield, VA 23235, United States.
  • DeVeaugh-Geiss A; Indivior, Inc, North Chesterfield, VA 23235, United States.
  • Bickel WK; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States. Electronic address: wkbickel@vtc.vt.edu.
Drug Alcohol Depend ; 234: 109389, 2022 05 01.
Article en En | MEDLINE | ID: mdl-35287034
ABSTRACT

BACKGROUND:

Opioid use disorder (OUD) seriously impacts public health in the United States. However, few investigations of long-term outcomes following treatment with medication for OUD exist. Additionally, these studies have prioritized opioid use and treatment utilization outcomes, and a gap in knowledge regarding long-term, multidimensional trajectories of OUD recovery exists. This study investigated a diverse array of outcomes for individuals with OUD at an average of 4.2 years post clinical trial participation.

METHODS:

Individuals who previously participated in long-acting buprenorphine subcutaneous injection clinical trials (NCT023579011; NCT025100142; NCT02896296) and enrolled in The Remission from Chronic Opioid Use-Studying Environmental and SocioEconomic Factors on Recovery (RECOVER; NCT03604861) Study participated in a follow up assessment (n = 216). Substance use, psychosocial, opioid dependence, and delay discounting outcomes were assessed. Regression analyses were conducted to determine significant associations between psychosocial/opioid dependence variables and both recent opioid use and delay discounting.

RESULTS:

The majority of participants reported abstinence from opioids since the last RECOVER study assessment (mean 2.26 years; 55%) and in the past 30 days (69%). Participants reported low levels of depression and psychological distress. Positive associations between depression and opioid craving with past 30-day opioid misuse and delay discounting, and negative associations between quality of life and treatment effectiveness with these outcomes were observed.

CONCLUSIONS:

This study examined longer term OUD recovery outcomes. Participants reported high levels of abstinence from opioids and psychosocial functioning. These encouraging results highlight the multidimensional nature of recovery from OUD, and further support the effectiveness of buprenorphine as an OUD treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Problema de salud: 2_sustancias_psicoativas / 8_opioid_abuse Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Drug Alcohol Depend Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Problema de salud: 2_sustancias_psicoativas / 8_opioid_abuse Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Drug Alcohol Depend Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...